A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
Phase I | Unknown Sites
What is the purpose of this trial?
To study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in patients with Advanced Solid Tumors
- Ages18 years and older
- Trial withStemline Therapeutics, Inc.
- Start Date08/18/2016
- End Date11/30/2019
- Last Updated05/29/2020
- Study HIC#1511016798